Not all breast cancers respond to the same therapies, and patients vary in their immune response potential. This study aims to tailor immunotherapy to each patient’s individualized “immuno-fingerprint,” with the goal of maximizing treatment efficacy and improving outcomes for all breast cancer patients. This work explores biochemical modifications to the tumor microenvironment and innovative immunotherapeutics to enhance anti-cancer immunity. The ultimate goal is to advance personalized treatment strategies that reduce patient suffering and move closer to eradicating breast cancer.

About Dr. Schneider:

Dr. Schneider is a breast cancer researcher at Rush University Medical Center whose work focuses on enhancing immunotherapy efficacy through detailed study of the tumor microenvironment and immune system interactions. Drawing on a multidisciplinary background in infectious disease, antibody manipulation, and advanced imaging, he has developed in vivo imaging protocols to track breast cancer immunotherapeutics and modified agents such as IL15Ra-Fc to improve immune responses. His research also explores altering the tumor microenvironment to increase therapeutic effectiveness, particularly in triple-negative breast cancer. Dr. Schneider is dedicated to developing innovative, patient-tailored approaches to improve treatment outcomes.